HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

Leucine-rich Repeat and Immunoglobulin Domain-containing Protein-1 (Lrig1) Negative Regulatory Action toward ErbB Receptor Tyrosine Kinases Is Opposed by Leucine-rich Repeat and Immunoglobulin Domain-containing Protein 3 (Lrig3)

(2013) Hanine Rafidi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth

(2013) G. Mahlknecht et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

(2013) Grit S. Herter-Sprie et al.   Frontiers in Oncology

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

(2012) Libero Santarpia et al.   BREAST CANCER RESEARCH AND TREATMENT

Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization

(2012) Yibing Shan et al.   CELL

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression

(2012) Ramona Schulz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Identification of the Coexisting HER2 Gene Amplification and Novel Mutations in the HER2 Protein-Overexpressed Mucinous Epithelial Ovarian Cancer

(2011) Wea-Lung Lin et al.   ANNALS OF SURGICAL ONCOLOGY

Endoplasmic reticulum is a main localization site of mTORC2

(2011) Delphine R. Boulbés et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

(2011) R. Ghosh et al.   CANCER RESEARCH

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

(2011) Phuong K. Morrow et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

(2011) M. Scaltriti et al.   MOLECULAR CANCER THERAPEUTICS

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

(2011) B N Rexer et al.   ONCOGENE

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

(2010) Francisco J. Esteva et al.   AMERICAN JOURNAL OF PATHOLOGY

Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation

(2010) Ke Liang et al.   CANCER CELL

Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

(2010) X. Huang et al.   CANCER RESEARCH

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

(2010) Simon Pacey et al.   INVESTIGATIONAL NEW DRUGS

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Heritable Variation of ERBB2 and Breast Cancer Risk

(2009) J. P. Breyer et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Her4 and Her2/neu Tyrosine Kinase Domains Dimerize and Activate in a Reconstitutedin VitroSystem

(2009) John Monsey et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

(2009) Francisco J. Esteva et al.   Nature Reviews Clinical Oncology